Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.066 SEK | +11.64% | +12.32% | +8.77% |
05-23 | Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy | CI |
05-21 | Transcript : Cantargia AB, Q1 2024 Earnings Call, May 21, 2024 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+8.77% | 63.05M | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- CANTA Stock
- News Cantargia AB
- Cantargia AB Announces Executive Changes